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dence interval 67-83%) of instances compared with the control method (25%, 95%CI 
17-33%), and among 83% (95%CI 76-91%) of positively-GDP-associated cancers 
compared with 17% (95%CI 9-24%) for the control method. There was no significant 
difference between the two methods for negatively-GDP-associated cancers. In 
terms of the relative magnitude of change compared to the actual incidences, there 
was no significant difference between the GDP-based forecast incidences and the 
control (mean magnitude difference 3.8%, 95% CI -3.5% - 11.0%). ConClusions: 
During epidemiological transition, cancer incidence is unlikely to remain static 
and so developing a proxy variable to evaluate risk over time is important. Using 
GDP as a proxy variable is preferable to the alternative of projecting historical 
values forward unchanged in terms of directional effect. However our study found 
no significant difference in terms of relative magnitude of the change over time. 
This latter result may be due to a small sample size of registries, indicating a need 
for further research.
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objeCtives: Bevacizumab (BEV) has proven to be efficacious to delay ovarian can-
cer progression and in controlling ascites. Significant overall survival (OS) benefits 
were reported in GOG218 patients with ascites at baseline, however, not in the ITT 
population. This raises questions about the potential role of “progression-driven 
cross-over” in confounding OS trial results. The objective of this study was to use 
decision-analytic modeling to estimate the potential impact of this “cross-over bias” 
in a RCT. Methods: A decision-analytic Markov model with 6 mutually exclu-
sive health states was built simulating OS as reported in GOG218. In the base case 
analysis, a 49 month time horizon was used (trial length). Input parameters were 
based on trial data and published literature. The model was calibrated to estimate 
the amount of patients developing ascites and switching. The model was then used 
estimating the unbiased treatment effect as it would have been observed without 
switching. Results: The model provided similar survival curves as reported. When 
switching treatment was disabled, the relative risk reduction for OS due to BEV 
compared to placebo changed from 11% to 32% over the 49 month time horizon. The 
results were sensitive to changes in the input parameter of switching, developing 
severe ascites and mortality after progression. ConClusions: Decision-analytic 
methods are suitable for describing causal relations and the impact of a potential 
bias. We estimated that about two thirds of the true treatment effect could not be 
captured in the biased data analysis. However, a formal adjustment of the original 
RCT data was not feasible due to lack of clinical trial data describing switching 
patterns. As crossover bias cannot always be avoided by trial design due to ethical 
reasons, we recommend collecting sufficient confounding variables determining 
cross-over so that specific statistical methods for causal-inference can be applied 
to control the cross-over bias.
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objeCtives: To examine the new co-payment scheme for prescribed medications 
introduced in Spain in 2012 and to explore differences in patient and National 
Health Service (NHS) drug cost co-payments between the old and the new schemes, 
using an example in a modelled patient population with coronary heart disease 
(CHD). Methods: The new legislation was researched and the new co-payment 
scheme was summarised in a flowchart. A published economic evaluation of drug-
eluting versus bare metal stents for high-risk patients with CHD was used to calcu-
late co-payments for the total cost of a prescribed drug (clopidogrel) from patients 
and from the NHS. The patient contribution was estimated from the income and 
expected work status of the model’s population. Results: In the new co-payment 
scheme, pharmacy-dispensed drugs are divided into three categories, using the 
Anatomical, Therapeutic, and Chemical classification system: 1) reimbursed with 
reduced contribution (4.26 € per prescription in 2014), 2) reimbursed without reduced 
contribution (ranging from 40% to 60%, depending on declared incomes for active 
workers, and from 10% to 60% for retired people) and 3) not reimbursed. Monthly 
limits for retired people (in 2014) range from 8.26 € to 62 € , with a monthly limit 
of 0.426 € for long-term, chronic conditions. The current, monthly, over-the-coun-
ter price of clopidogrel is 22.92 € . Under the old co-payment scheme, the model 
estimated that the average NHS payment was 19.62 € per patient (86% of the cost). 
Under the new scheme, this amount was estimated at 16.55 € (72%). The NHS con-
tribution decreased by 14%. ConClusions: The new scheme results in a signifi-
cant reduction to drug-related NHS co-payment contributions. This reduction could 
lead to significant changes in incremental cost-effectiveness ratio estimates. It is 
recommended that this adjustment be made in economic evaluations developed 
or adapted for Spain.
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objeCtives: Genetic screening identifies candidates for intensified cancer 
screening and prevention. Due to the high cost of genetic testing, it is impor-
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objeCtives: To compare homogeneous (HMM) versus non-homogeneous Markov 
models (NHMM) for cost-effectiveness analysis (CEA) of routine use of transparent 
dressings containing a chlorhexidine gluconate gel pad versus standard trans-
parent dressings. The antimicrobial dressing protects central vascular accesses 
reducing the risk of catheter-related bloodstream infections (CRBSIs) in intensive 
care units (ICU). The impact of the modeling approach on the decision of adopt-
ing antimicrobial dressings for critically-ill patients is discussed. Methods: 
Comparative clinical efficacy data from a multicentre randomized controlled trial 
(RCT) enrolling 1,879 patients and economical data from micro and macro-costing 
published studies were combined. The HMM and NHMM models were built sepa-
rately using the same sources. The statistical unit was the ICU patient and the ICU 
perspective was chosen. Probabilistic sensitivity analyses (PSA) were conducted 
for both models for comparing the robustness of the CEA results. Results: The 
difference in clinical outcomes between each dressing strategies was statisti-
cally significant with both models while cost differences were not. The PSA with 
the NHMM resulted in 11.8 infections avoided per 1,000 patients (95%CI: [3.85; 
19.64]) and a mean extra cost of € 141 per patient (95%CI: [€ -975; € 1,258]) when 
using antimicrobial dressing. The PSA with the HMM resulted in 6.45 infections 
avoided per 1,000 patients (95%CI: [0.15; 12.75]) and the mean extra cost of € 252 
per patient (95%CI: [€ -924; € 1,428]). ConClusions: The antimicrobial dressings 
are consistently more efficacious in preventing CRBSIs whatever the model used. 
The HMM is less sensitive to simulate the real life of the ICU patients. Regardless 
the model approach chosen the antimicrobial strategy is more efficacious than 
the comparator, but its probability of being cost-effective is comparatively reduced 
with the HMM. Time dependent approach (NHMM) seems to be better adapted to 
model rare events as CRBSIs.
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objeCtives: Autosomal dominant polycystic kidney disease (ADPKD) is a major 
cause of end-stage renal disease (ESRD) affecting approximately 4 per 10,000 people 
in Europe. There is a paucity of research regarding the natural history of ADPKD 
progression. This study aimed to utilise the results of a systematic literature review 
characterising predictors of ADPKD progression to construct a natural history dis-
ease model for ADPKD. Methods: An individual patient-level lifetime simulation 
was developed in Microsoft Excel, driven by baseline and time-dependent age, esti-
mated glomerular filtration rate (eGFR) and total kidney volume (TKV). Rates of 
progression were informed by a large naturalistic study. Dialysis modality, transplant 
status and disease-specific mortality were also modelled. Relevant ADPKD compli-
cations were stratified by chronic kidney disease stages. Modification of disease 
progression rate was investigated in order to assess the potential of the model 
for evaluating treatment interventions. Results: On visual inspection, modelled 
and published eGFR trajectories for the general ADPKD patient were consistent 
(median age at ESRD of approximately 55 years). When patients are stratified by 
baseline TKV the model predicts variable rates of progression to ESRD, aligning with 
the assertion that the baseline TKV is the most important prognostic indicator for 
ADPKD progression. Modification of the risk equations to incorporate the impact of 
an intervention has shown promise to estimate important outcomes such as delay 
to ESRD. ConClusions: The model has demonstrated both face and predictive 
validity and is capable of predicting outcomes consistent with those reported in the 
ADPKD literature. It represents the first model capable of informing on important 
clinical outcomes relevant to both clinicians and patients, such as time to ESRD, 
with the potential to evaluate the long-term impact of treatment interventions on 
ADPKD progression.
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objeCtives: To validate the use of change in Gross Domestic Product per capita 
(GDP) as a proxy for forecasting change in cancer risk. Methods: Using data from 
the International Agency for Research on Cancer (IARC) and GDP data from the 
World Bank, the correlation between the incidence of five cancers (breast, prostate, 
lung, liver, and colorectal) in 147 countries for 1993-1997 (midyear 1995), and the 
corresponding GDP was calculated. We used this correlation to retrospectively 
forecast the 2005 incidence for five cancers in four cities (Cali, Colombia; Delhi, 
India; Shanghai, China; St. Petersburg, Russia). The GDP-based forecasts were com-
pared to a control assuming no change in incidence from the IARC incidence data 
for 1998-2002 (midyear 2000). The two forecast estimates with the actual reported 
IARC 2003-2007 incidence data were compared. Results: Overall, the GDP-based 
method correctly forecasts the directional change in incidence in 75% (95% confi-
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bACKGRound: Companion diagnostics (CD) testing aims to stratify the patient 
population. It conditions the choice of best available therapeutic options, limiting 
targeted therapy (TT) to subgroups most likely to benefit and triggers potential cost 
savings. objeCtives: To provide a general framework and a list of key methodo-
logical points to be addressed while conducting a model-based economic evaluation 
of CD-TT pairings, especially in oncology. Methods: Based on a health economic 
literature review and a clinical expert panel with examples drawn from cases of CD 
testing selection biomarker predictive of the response level towards an anti-cancer 
TT. Results: As CD and TT have embedded values, it is important to assess them 
concomittantly within a shared modeling framework. We propose a decision tree to 
model the patient population stratification and to incorporate impacts of analytical 
and clinical validity. The former refers here to the inability of the CD to accurately 
and reliably inform the biomarker resulting in true (false) positive/negative cases, 
whereas the latter relates to the penetrance, i.e. the strength of association between 
the biomarker and clinical phenotypes (treatment effect). Such parameters are crucial 
especially in cases multiple distinct lab-tests (commercial vs. home-brew, technics, 
amount of informations provided regarding the biomarker). Each patient sub-group 
outcomes are required to be modeled (costs and health effects). A Markov state-tran-
sition model either based on treatment pathway and/or disease staging represents 
both adequate approaches to simulate the clinical outcomes, incorporating specific 
efficacy parameters per sub group depending on their biomarker expression levels. 
In instances, time spent until the CD result delivery exceeds a clinical significant 
threshold, testing delay shall be modelled such as all parameters driving loss of oppo-
runity. ConClusions: Beyond reasonable simple binary-type of selection biomarker, 
more complex types of biomarkers and CD technologies (full sequences) has risen 
additional complexity and poses new methodological challenges.
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objeCtives: Quantitative patient preferences are increasingly considered for health 
care policy decisions. The objective of this study is to develop a methodology to 
combine patient preferences with clinical evidence in a multi-criteria framework 
that takes into account uncertainty in both preferences and clinical evidence. The 
methodology will be illustrated with a case on antiretroviral treatments. Methods: 
Treatments under consideration are eight highly active antiretroviral therapies 
(HAART) recommended for treatment-naïve patients by the National Institute of 
Health. The treatments are compared on the probabilities of virologic failure, hyper-
sensitivity reaction, bone damage, and kidney damage; and on the treatability of 
bone/kidney damage. Preferences from 147 patients were elicited with a discrete 
choice method in an earlier study. Preferences were assumed to be distributed with 
a multivariate normal distribution. Treatment performances as identified from clini-
cal trials were assumed to be distributed with beta distributions. The probability 
distributions around preferences and clinical performances were combined with a 
Monte Carlo simulation method to estimate the joint probability distribution around 
each treatment’s patient-weighted utility. Results: The three treatments with the 
highest mean patient-weighted utility were dolutegravir+abacavir/lamivudine (-0.4, 
95% CI: -1.3 to 0.5), raltegravir+tenofovir/emtricitabine (-0.5, 95% CI: -1.6 to 0.7) and 
darunavir/ritonavir+tenofovir/emtricitabine (-0.6, 95% CI: -2.0 to 0.8). There was con-
siderable overlap between the probability distributions of patient-weighed utilities 
(probability of first rank reversal: 49%; probability of any rank reversal: > 99%). When 
ignoring uncertainty around patient preferences, the probability of a first rank rever-
sal dropped to 12%, and that of any rank reversal dropped to 88%. ConClusions: 
A probabilistic multi-criteria methodology was developed that explicitly combines 
patient preferences and clinical evidence. The individual or joint impact of uncer-
tainty in these on the treatments’ patient-weighted utilities is assessed. Although 
limited by the small number of attributes, the illustrative case suggests the choice 
of HAART is highly sensitive to patient preferences.
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objeCtives: Cross-sectional studies showed that, for modelling health-related 
quality of life (HRQoL), beta regression is superior in terms of fit and predictive accu-
racy to other commonly used methods based on normality distribution assumption. 
Although, longitudinal HRQoL measurements are widely used in clinical trials, not 
much is known about beta regression suitability in this context. This is mainly due 
to software unavailability with classical estimation methods. This study proposes 
to model the longitudinal HRQoL outcome using a mixed beta regression estimated 
by Bayesian Markov chain Monte Carlo (MCMC) methods implemented in WinBUGS. 
Compared to the classical approach, not only the Bayesian estimation is consider-
ably easier to implement but has other advantages; for example, the possibility of 
including informative priors, enabling analysts to incorporate multiple sources of 
evidence in a single model. Methods: We used a 16-year longitudinal follow-up 
for modelling the relationship between SF-6D HRQoL and variables age, gender and 
mortality risk by means of a mixed beta regression. Besides modelling the mean 
tant to identify patients who are most likely to benefit. Doing so using clini-
cal trials is prohibitively expensive; thus a mathematical modeling approach is 
required. Methods: We developed a framework for stratified cost-effectiveness 
analysis using individual-based discrete-event simulations, consisting of a natu-
ral history component that captures mutation distribution, correlations between 
mutation and other risk factors (e.g. family history), and cancer incidence, progres-
sion and mortality, and a health care process component that captures interac-
tions between the patients and the health care system, through genetic testing, 
screening, diagnosis and treatment, and their costs. The genetic screening strat-
egy consists of 3 steps: a benefit- risk assessment step, in which patients are 
assessed for risk of carrying mutations and potential benefits from genetic testing, 
a genetic testing step, in which qualified patients within an optimal risk bracket 
are given the appropriate tests and an intervention step, in which patients are 
given care based on the results from the genetic tests. Results: We use the fol-
lowing approach to explore and identify optimal strategies for 3 genetic screening 
applications: Dinh et al. demonstrated that primary screening for Lynch syndrome 
in patients at least 25 years old and with a risk of at least 5% was cost effective. 
Folse et al. showed that single-nucleotide polymorphism (SNP) screening for breast 
cancer risk for recommending patients to MRI screening was most cost-effective 
in women age 40 with a lifetime risk of 16 to 28%. Green et al showed that the 
same genetic test for recommending patients to chemoprevention was most cost-
effective for women age 50-59 with a 5-year risk of 1.2-1.66%. ConClusions: As 
more genetic tests becomes available, this method can be used to identify screen-
ing strategies that maximize cost-effectiveness.
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objeCtives: To develop a flexible and computationally efficient discrete event 
simulation (DES) model which could be employed in a cost-effectiveness analysis 
comparing the use of PET-CT scans versus current diagnostic procedures for Conn’s 
disease in hypertensive patients. Methods: Visual Basic was used for the model 
simulation with Microsoft Excel constituting the front-end software. In order to 
ensure a high level of flexibility, individual patients could be assigned a number 
of personal traits and the clinical, cost and utility inputs were easily adjustable. 
Individual diagnostic procedures were programmed in separate modules with the 
aim of simplifying potential modifications to the diagnostic pathway. Results: 
A DES was constructed to evaluate the cost-effectiveness of new treatments based 
on the experience of patients assigned to intervention and comparator arms. 
Patients were considered individually in each arm, using the same background 
mortality. Time, gender and event dependent risk equations enabled efficient model-
ling of endogenous heterogeneity of the population. Continuous time accounting 
allowed for the modelling of competing adverse events and provided a realistic 
representation of patients’ experience. Preliminary results indicate that the 
use of PET-CT scans for the screening of Conn’s syndrome could be cost-effec-
tive. ConClusions: The newly developed model is the first formal attempt to 
evaluate the cost-effectiveness of this alternative screening technique for hyper-
tensive patients who are suspected of suffering from Conn’s disease. The model will 
be further developed to include probabilistic sensitivity analysis and bootstrapping 
in order to evaluate the robustness of the potential results. Evolutionary algorithms 
will be incorporated to define the most optimal solution from the continuous spec-
trum of potential screening strategies. As the model will utilise actual patient level 
data, it could be used by the decision maker to determine the most cost-effective 
diagnostic strategy.
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objeCtives: Patients’ experience of OIC may be unstable, with periods of con-
stipation and non-constipation, an observation supported by physician reports. 
There is, however, a lack of quantitative evidence of this experience. Such evidence 
would be valuable to inform development of economic models for OIC treatments. 
The objective of this abstract is to fill this gap utilizing data from two pivotal 
Naloxegol studies, KODIAC 4 and 5, which demonstrated significant improvements 
in SBM frequency response compared to placebo over 12 weeks. Methods: 892 
non-cancer pain patients with OIC were randomized to Naloxegol 25 mg or pla-
cebo in two pivotal studies. A 4-week rolling determination of OIC and non-OIC 
status at weeks 4 through 12 was used in time-to-event analyses. Patients were 
considered OIC if they reported < 3 SBMs for > = 2 out of the 4 weeks and non-OIC 
if reported > = 3 SBMs for > = 3 out of 4 weeks. Those with non-OIC status at week 
4 were selected as the baseline and first observed OIC status was considered an 
event. Parametric analyses with Exponential, Weibull, Gompertz, Log-normal, Log-
logistic, and Generalized Gamma distributions were conducted. Results: Based 
on the parametric time-to-event analysis results, the Log-normal distribution was 
selected as the best fit and provided plausible long term projections. Naloxegol had 
a noticeable separation for extending the time to first OIC event when compared 
to placebo over the projected long-term follow-up. ConClusions: This research 
demonstrates that the natural fluctuation between OIC and non-OIC is substantial 
and requires integration into an economic model. Even in the absence of treat-
ment, a substantial proportion of patients become non-OIC, and a significant 
proportion of these remain in non-OIC subsequently. Nevertheless, a treatment 
effect for Naloxegol was observed over and above this ‘background’ placebo vari-
ation in the experience of OIC.
